Mouse hepatocytes lacking mGlu5 metabotropic glutamate receptors are less sensitive to hypoxic damage

Marianna Storto1, Giuseppe Battaglia, Roberto Gradini

  • 1I.N.M. Neuromed, Pozzilli, Italy.

Insights

Endogenous activation of type-5 metabotropic glutamate receptors (mGluR5) contributes to liver cell injury during hypoxia. Blocking mGluR5 protected liver cells from hypoxic damage, confirming its role in cell injury.

Area of Science:

  • Neuroscience
  • Hepatology
  • Cellular Biology

Background:

  • Endogenous activation of type-5 metabotropic glutamate receptors (mGluR5) is implicated in hypoxia-induced liver cell injury.
  • Understanding the precise role of mGluR5 in hepatic response to hypoxia is crucial for developing therapeutic strategies.

Purpose of the Study:

  • To investigate the contribution of mGluR5 to hypoxia-induced liver cell injury.
  • To evaluate the protective effects of mGluR5 antagonism against hypoxic liver damage.

Main Methods:

  • Utilized glutamate mGlu5 receptor knockout mice to assess cellular sensitivity to hypoxia.
  • Isolated hepatocytes from knockout and wild-type mice for comparative analysis.
  • Measured lactate dehydrogenase release and reactive oxygen species formation as indicators of cell damage.
  • Administered the mGlu5 receptor antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), to evaluate its protective effects.

Main Results:

  • Hepatocytes from mGluR5 knockout mice exhibited reduced sensitivity to hypoxic cell damage compared to wild-type controls.
  • Lactate dehydrogenase release was significantly lower in hepatocytes from knockout mice.
  • Formation of reactive oxygen species was diminished in hepatocytes lacking mGluR5.
  • Treatment with MPEP demonstrated a protective effect on hepatocytes against hypoxic injury.

Conclusions:

  • Endogenous activation of mGluR5 plays a significant role in mediating hypoxia-induced liver cell injury.
  • mGluR5 knockout or antagonism provides protection against hepatic damage under hypoxic conditions.
  • Targeting mGluR5 presents a potential therapeutic avenue for managing liver injury associated with hypoxia.

Related Concept Videos